Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

Inclusion Criteria: * Histologically confirmed malignant glioma, including any of the following: * Glioblastoma multiforme (GBM) * Gliosarcoma (GS) * Anaplastic astrocytoma (AA) * Anaplastic oligodendroglioma (AO) * Anaplastic mixed oligoastrocytomas (AMA) * Malignant astrocytoma not otherwise specified (NOS) * Prior low-grade glioma allowed provided there is histologic evidence of progression to a malignant glioma * Must meet the following criteria for phase I: * All types of malignant gliomas allowed * No limitations on the number of relapses * Must meet the following criteria for phase II: * Only patients with GBM or GS are allowed * Must be in first, second, or third relapse * patients who had prior therapy (must include external beam radiotherapy) for a low-grade glioma that is considered standard, non-surgical treatment for a high-grade glioma, the surgical diagnosis of high-grade glioma will be considered the first relapse * Must have shown unequivocal radiographic evidence for tumor progression by MRI or CT scan and have either measurable or evaluable disease * Measurable disease is defined as bidimensionally measurable lesions with clearly defined margins by MRI scan * Evaluable disease is defined as unidimensionally measurable lesions or masses with margins not clearly defined * Karnofsky performance status ≥ 60% * Life expectancy \> 8 weeks * Absolute neutrophil count ≥ 1,500/μL * Platelets ≥ 100,000/μL * Total bilirubin \< 2.0 x upper limit of institutional normal (ULN) * AST \< 2.0 x ULN * Creatinine \< 1.5 x ULN * Fasting serum triglycerides \< 2.5 x ULN * Fasting serum cholesterol \< 350 mg/dL * Women of child-bearing potential and men must agree to use adequate contraception (i.e., hormonal or barrier method of birth control) prior to study entry and for the duration of study participation * Recovered from all toxicities associated with prior surgery, radiotherapy, or chemotherapy * At least 1 week since prior surgery * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) * At least 12 weeks since prior radiation therapy * Must not receive any P450-enzyme-inducing anticonvulsants (EIAC) for at least 2 weeks prior to and during participation in this trial Exclusion Criteria: * Women who are pregnant or lactating * History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib hydrochloride or sirolimus * Uncontrolled intercurrent illness including, but not limited to, any of the following: * Ongoing or active infection requiring IV antibiotics * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Hyperlipidemia (e.g., grade 3 or greater hypercholesterolemia or hypertriglyceridemia) not controlled with medication * Psychiatric illness or social situations that would limit compliance with study requirements * Disorders associated with significant immunocompromise (e.g., HIV or systemic lupus erythematosus \[SLE\]) * Patients with another primary malignancy that has required treatment other than surgery within the past year (except for nonmelanoma skin cancer or carcinoma in situ) * Patients with the inability to comply with the protocol requirements in the opinion of the investigator including those who can not take oral medications * Patients who are unable to undergo routine imaging evaluations with magnetic resonance imaging scans * Prior EGFR-directed or mTOR-directed therapies including sirolimus or sirolimus analogs * Patients taking concurrent immunosuppressive agents other than prescribed corticosteroids * Concurrent antineoplastic or antitumor agents that are not part of the study therapy including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer therapy * Blood products during cycle 1 unless a patient experiences hematologic DLT or if it is medically imperative to administer a transfusion * Concurrent grapefruit or grapefruit juice * Other concurrent investigational agents * Receiving concurrent enzyme-inducing antiepileptic drugs